Lannett Company's Lisdexamfetamine Dimesylate Recalled by FDA Over Content Uniformity Failure
Lannett Company, Inc. initiated a nationwide Class II recall for 1,608 bottles of Lisdexamfetamine Dimesylate Capsules (10 mg) due to failed content uniformity specifications. This FDA-terminated recall highlights critical quality control issues for procurement directors and regulatory affairs heads, necessitating immediate supply chain review and enhanced supplier due diligence for Lannett's products.
FDA Class II Recall: Lannett's Lisdexamfetamine Dimesylate Fails Content Uniformity
Lannett Company, Inc. has executed a nationwide Class II recall, designated D-0112-2025, for its Lisdexamfetamine Dimesylate Capsules, 10 mg. The critical reason for this recall, initiated by the firm on October 25, 2024, was a failure to meet action limits for stratified content uniformity specifications. This specific quality defect impacts Lot: 23274856A, with an expiration date of April 30, 2025. A total of 1,608 bottles, each containing 100 capsules, were distributed across the United States, making this a significant event for supply chain managers. For procurement directors, this incident underscores the imperative of stringent quality control in pharmaceutical manufacturing, particularly for controlled substances like Lisdexamfetamine Dimesylate (ANDA215802). A failure in content uniformity directly compromises patient safety by risking inconsistent dosing, which can lead to sub-therapeutic effects or adverse reactions. Regulatory affairs heads must note the Class II classification, indicating that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This necessitates a thorough review of Lannett's quality assurance processes for all products sourced from them.
Commercial Implications for Lisdexamfetamine Dimesylate Supply Chains
The recall of Lannett's Lisdexamfetamine Dimesylate Capsules, a human prescription drug administered via the oral route, carries direct commercial implications for entities involved in its distribution and dispensing. As a generic equivalent (ANDA215802), Lisdexamfetamine Dimesylate is a critical medication, and any disruption, even for a specific lot of 1,608 bottles, demands immediate attention from supply chain VPs. The nationwide distribution pattern means that the affected lot could have reached numerous pharmacies and healthcare providers across the USA. Procurement directors must promptly verify their inventory against Lot: 23274856A to ensure no non-compliant product remains in their supply chain. While the recall was voluntarily initiated by Lannett Company, Inc. and communicated via letter, the underlying quality issue reflects on the manufacturer's operational integrity. Business development executives should consider the potential impact on Lannett's reputation and future market opportunities, especially concerning new product launches or expansions where robust quality systems are paramount. This event highlights the necessity for diversified sourcing strategies to mitigate risks associated with single-supplier quality lapses for essential medications.
Lannett's Regulatory Response and Recall Resolution Status
Lannett Company, Inc.'s handling of the Lisdexamfetamine Dimesylate recall, initiated on October 25, 2024, was classified as 'Voluntary: Firm initiated,' indicating that the company identified the quality deviation internally or responded proactively to initial findings. The FDA subsequently classified the recall on December 5, 2024, and officially terminated it on June 27, 2025. The 'Terminated' status signifies that the FDA has concluded that the recalling firm has successfully removed or corrected the product from the market, and the issue for the specific recalled lot (23274856A) is considered resolved. For regulatory affairs heads, this termination is a critical data point, confirming the immediate regulatory action is complete. However, it does not erase the initial quality control failure. Business development executives should understand that while the immediate crisis is over, future FDA inspections at Lannett's Seymour, IN facility, located at 1101 C Ave W, Seymour, IN 47274-3342, will likely scrutinize the root cause analysis and the effectiveness of the corrective and preventive actions (CAPAs) implemented to address the content uniformity issue. This ongoing scrutiny could influence future product approvals or manufacturing site clearances.
Strategic Implications for Pharmaceutical Procurement and Quality Assurance
This recall event involving Lannett Company, Inc. serves as a critical case study for senior decision-makers in the global chemical and life sciences industry, particularly for procurement directors and regulatory affairs heads. The failure in stratified content uniformity for Lisdexamfetamine Dimesylate underscores the inherent risks in pharmaceutical manufacturing and the absolute necessity for robust quality management systems. Procurement teams must move beyond simple cost considerations and prioritize comprehensive supplier qualification that includes rigorous audits of manufacturing processes and quality control data, especially for products with narrow therapeutic indices or controlled substance classifications. Supply chain VPs should assess their current reliance on Lannett for other products and consider diversifying their supplier base to minimize exposure to similar quality-related disruptions. Furthermore, regulatory affairs departments should leverage such incidents to review and strengthen their internal pharmacovigilance and quality monitoring programs, ensuring that any deviations are detected early and addressed swiftly. This proactive approach is vital for maintaining product integrity, ensuring patient safety, and safeguarding business continuity in a highly regulated environment.
Future Regulatory Landscape and Manufacturer Accountability
The FDA's classification and subsequent termination of Lannett's Lisdexamfetamine Dimesylate recall highlights the agency's continuous oversight and the manufacturer's accountability. While the voluntary nature of the recall and its termination are positive indicators of Lannett's response, the incident itself reinforces the FDA's unwavering expectation for adherence to Current Good Manufacturing Practices (cGMP). For business development executives, understanding this regulatory environment is crucial when evaluating partnerships or acquisitions involving manufacturers with recent quality issues. The Seymour, IN facility, as the location associated with the recall, will remain under the FDA's watchful eye for future inspections, with a particular focus on the efficacy of implemented CAPAs for content uniformity. This scrutiny can impact the speed of new product approvals or facility expansions. Procurement directors must integrate such recall data into their supplier performance metrics, ensuring that quality and compliance are weighted heavily alongside commercial terms. This ongoing vigilance is essential for mitigating future supply chain risks and maintaining consumer trust in pharmaceutical products distributed nationwide in the USA.